OBJECTIVES: To investigate patterns of hemostat methods in surgeries and evaluate the healthcare resource utilization and economic burden of patients in China. METHODS: All Patients using oxidized regenerated cellulose (ORC), microfibrillar collagen hemostat (MCH), resorbable oxidized cellulose (ROC), and microporous polysaccharide hemispheres (MPH) after cholecystectomy, hysterectomy or other related surgeries in tertiary hospitals were identified from the 2012 dataset of the China Health Insurance Research Association (CHIRA) claims database which includes a nationwide, cross-sectional sampling of inpatients. Direct medical costs included diagnostic tests, surgery, physiotherapy, hemostat, medicines and consumables cost. Descriptive statistics were used to describe patient profiles, healthcare resource utilization and direct medical cost. Two-tailed tests were performed at 95% confidence. Multiple linear regression (MLR) was used to identify main parameters that may influence inpatient costs thus providing patient selection criteria for a relative unbiased comparison. RESULTS: A total of 788 patients with the following characteristics, age, gender, surgery types, hemostats types, Length of Stay (LOS), Hospital tier were identified. Factors significantly impacted inpatient cost were Length of Stay, type of hemostat (ORC vs. others), tier of Medical Institute (MLR, p<0.01). Among 382 patients who stayed at Tier 3 hospitals with LOS ≤14 days, the average inpatient costs of patients using ORC vs. other hemostats (MCH, ROC, MPH) were 21,101 RMB (±21,390), 23,246 RMB (±15,545), respectively. There was a significant difference in inpatient costs (p<0.01) between the 2 groups. CONCLUSIONS: The economic burden of patients using new bio-surgical hemostatic materials was considerable. While a number of factors affected inpatient costs, patients using ORC were associated with lower total inpatient expenditure.